Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have received an average rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $18.30.

YMAB has been the topic of several recent research reports. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Bank of America cut their price objective on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price for the company. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. Finally, Truist Financial reduced their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th.

Y-mAbs Therapeutics Stock Down 1.4 %

Shares of YMAB stock opened at $5.09 on Wednesday. Y-mAbs Therapeutics has a 52 week low of $4.25 and a 52 week high of $17.78. The stock has a fifty day moving average of $5.66 and a 200 day moving average of $9.65. The firm has a market capitalization of $230.16 million, a price-to-earnings ratio of -9.43 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the previous year, the business earned ($0.02) EPS. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. The trade was a 5.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in YMAB. Principal Financial Group Inc. purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at about $267,000. Intech Investment Management LLC purchased a new stake in Y-mAbs Therapeutics during the 3rd quarter valued at $133,000. Charles Schwab Investment Management Inc. lifted its position in Y-mAbs Therapeutics by 9.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock worth $3,676,000 after buying an additional 23,982 shares during the last quarter. FMR LLC increased its position in Y-mAbs Therapeutics by 23.1% during the third quarter. FMR LLC now owns 36,416 shares of the company’s stock valued at $479,000 after acquiring an additional 6,822 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at $44,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.